Loading company financials…
NASDAQ NMS - GLOBAL MARKET · Biotechnology · CIK 0001104506
$94.04
-1.70% · delayed ~15 min
Last price from Oct 21, 2026
$20.15B market value
From INSMED Inc's FY2025 10-K, filed Feb 19, 2026 · read the filing
INSMED develops and makes medicines. It took in $606.4M last year, which makes it a smaller company. It spends more than it earns — losing about 211 cents on every dollar of sales.
The financial picture is led by growth, with accounting worth watching, while profitability and debt remain weak.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Recent open-market selling by 3 insiders, not under a pre-arranged plan.
$35.7M sold in the last 120 days · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
A mixed picture — some clear strengths and some weaknesses.
From INSMED Inc's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Revenue
$363.7M → $606.4M
Gross profit
$278.0M → $483.5M
Operating income
-$878.3M → -$1.25B
Operating margin
-241.5% → -205.6%
Measured against FY2024, from the 10-K filed Feb 19, 2026
Improved: +66.7%
$363.7M to $606.4MCritical
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
How the latest move compares (quote delayed ~15 min), and what was published around it
INSM fell 1.70% on the latest quote. The average Health Care company tracked here moved +1.62%, and the S&P 500 −1.04%. That is 3.3 points below its sector and 0.7 points below the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
Opinions from 31 analysts covering this company, as of . Their views, not this site's.
Of 31 analysts publishing on this company, 9 say strong buy, 21 say buy and 1 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
The essentials
Each answered from the filings, with the numbers behind it.
No. It lost $1.28B last year, losing about 211 cents on every dollar of sales.
Yes, quickly. Sales grew 66.7% last year.
Yes — it carries debt while operations are consuming cash rather than generating it. For every $1 it owes, it owns $1.48 in assets. Its operating profit does not cover its interest bill — -14.88x against the interest it owes.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it lost $1.28B and generated -$935.0M of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 19, 2026Filing for FY2025 | FY202410-K · Feb 20, 2025Filing for FY2024 | FY202310-K · Feb 20, 2025Filing for FY2023 | FY202210-K · Feb 20, 2025Filing for FY2022 | FY202110-K · Feb 17, 2022Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $606.4M | $363.7M | $305.2M | $245.4M | $188.5M | +66.7% |
| Cost of revenue | $122.9M | $85.7M | $65.6M | $55.1M | $44.2M | +43.4% |
| Gross profit | $483.5M† | $278.0M† | $239.6M† | $190.2M† | $144.3M† | +73.9% |
| Gross marginGross profit ÷ revenueWhat is this? | 79.7% | 76.4% | 78.5% | 77.5% | 76.6% | +3.3 pts |
| Selling, general and administrative | $701.2M | $461.1M | $344.5M | $265.8M | $234.3M | +52.1% |
| Operating income | -$1.25B | -$878.3M | -$709.6M | -$457.3M | -$375.1M | −42.0% |
| Operating marginOperating income ÷ revenueWhat is this? | -205.6% | -241.5% | -232.5% | -186.4% | -199.0% | +35.9 pts |
| Interest expense | $83.8M | $84.9M | $81.7M | $26.4M | $40.5M | −1.3% |
| Income before tax | -$1.27B | -$910.1M | -$747.0M | -$480.2M | -$436.4M | −39.7% |
| Net income | -$1.28B | -$913.8M | -$749.6M | -$481.5M | -$434.7M | −39.7% |
| Net marginNet income ÷ revenueWhat is this? | -210.5% | -251.2% | -245.6% | -196.3% | -230.6% | +40.7 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $-5.96 | $-5.09 | $-5.07 | $-3.55 | $-3.66 | −17.0% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| INSMINSMED Inc · this page | 5.0/10 | 4/9 | 66.7% |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Was granted or awarded shares — 6,139 shares
Holds 6,139 shares after this filing.
Was granted or awarded shares — 6,139 shares
Holds 6,139 shares after this filing.
Sold on the open market
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Had a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingWrite down why you are following INSMED Inc, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 13 subsidiaries named in its 10-K, incorporated across 9 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from INSM's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 19, 2026), reported under the US GAAP taxonomy. View the source filing.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 5.0 | 4/9 | 10-K, filed Feb 19, 2026 |
| FY2024 | 6.0 | 3/9 | 10-K, filed Feb 20, 2025 |
| FY2023 | 6.0 | 3/9 | 10-K, filed Feb 22, 2024 |
| FY2022 | 6.0 | 3/9 | 10-K, filed Feb 23, 2023 |
| FY2021 | 4.0 | 3/9 | 10-K, filed Feb 17, 2022 |
| FY2020 | 6.0 | 3/9 | 10-K, filed Feb 25, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
4 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
3.59
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-1.93
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +73.9%
$278.0M to $483.5MCritical
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Deteriorated: $368.5M wider
-$878.3M to -$1.25BCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +35.9 pts
-241.5% to -205.6%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +40.7 pts
-251.2% to -210.5%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: -51.0%
$1.10B to $541.0MCritical
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Deteriorated: +19.4%
179.4M to 214.3MCritical
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
Changed: +48.5%
$21.9M to $32.6MCritical
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Deteriorated: $363.0M wider
-$913.8M to -$1.28BSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +3.3 pts
76.4% to 79.7%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Deteriorated: $261.8M wider
-$705.8M to -$967.6MSignificant
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Deteriorated: $0.87 wider
-$5.09 to -$5.96Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: -8.0%
$555.0M to $510.4MNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Aug 6, 2026 — read it.
Improved: +296.1%
$107.4M to $425.5MCritical
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +351.6%
$79.3M to $358.3MCritical
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: $311.3M narrower
-$312.9M to -$1.5MCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: $308.4M narrower
-$321.7M to -$13.2MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +10.3 pts
73.9% to 84.2%Critical
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +290.9 pts
-291.3% to -0.4%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +296.4 pts
-299.5% to -3.1%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: $1.46 narrower
-$1.52 to -$0.06Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: -57.6%
$1.28B to $544.8MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: +3.4%
211.1M to 218.3MNotable
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 6, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Improved: $151.8M narrower
-$153.3M to -$1.5MCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: $150.3M narrower
-$163.6M to -$13.2MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +49.8 pts
-50.1% to -0.4%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +50.3 pts
-53.5% to -3.1%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: $0.69 narrower
-$0.76 to -$0.06Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +39.1%
$306.0M to $425.5MSignificant
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +38.6%
$258.5M to $358.3MSignificant
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Deteriorated: -6.4%
$582.2M to $544.8MNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 6.4% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Trailing P/E is not meaningful because the latest trailing earnings are zero or negative. The price-to-book and price-to-sales figures below still provide reference points.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| -210.5% |
| — |
| 2.06x |
| BIIBBIOGEN INC. | 9.0/10 | 6/9 | 2.2% | 13.1% | 28.82x | 0.61x |
|---|
| ALNYALNYLAM PHARMACEUTICALS, INC. | 7.3/10 | 5/8 | 65.2% | 8.4% | 95.89x | 5.29x |
|---|
| INCYINCYTE CORP | 10.0/10 | 6/8 | 21.2% | 25.0% | 18.04x | 0.35x |
|---|
| NBIXNEUROCRINE BIOSCIENCES INC | 10.0/10 | 5/8 | 21.4% | 16.7% | 29.97x | 0.42x |
|---|
| Median of peers | 9.5/10 | — | 21.3% | 14.9% | 29.40x | 0.52x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Holds 39,238 shares after this filing.
Sold on the open market — 5,000 shares at $127.53 ($637.6K)
Holds 0 shares after this filing.
Exercised stock options — 82,280 shares at $13.67 ($1.1M)
Holds 181,024 shares after this filing.
Exercised stock options — 76,600 shares at $17.16 ($1.3M)
Holds 257,624 shares after this filing.
Exercised stock options — 80,970 shares at $30.46 ($2.5M)
Holds 338,594 shares after this filing.
Sold on the open market — 239,850 shares at $133.27 ($32.0M)
Holds 98,744 shares after this filing.
Exercised stock options — 18,278 shares at $18.95 ($346.4K)
Holds 78,764 shares after this filing.
Exercised stock options — 8,895 shares at $25.83 ($229.8K)
Holds 87,659 shares after this filing.
Sold on the open market — 8,895 shares at $127.00 ($1.1M)
Holds 78,764 shares after this filing.
Sold on the open market — 18,278 shares at $129.40 ($2.4M)
Holds 60,486 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 25,000 shares ($3.1M) on or after .
Shares originally obtained via Equity grant.
Filed notice to sell 5,000 shares ($637.6K) on or after .
Shares originally obtained via PURCHASED.
Filed notice to sell 239,850 shares ($32.0M) on or after .
Shares originally obtained via Stock Plan Activity.
Filed notice to sell 27,173 shares ($3.5M) on or after .
Shares originally obtained via Stock Plan Activity.
Filed notice to sell 10,700 shares ($1.1M) on or after .
Shares originally obtained via Stock Plan Activity.
Filed notice to sell 10,699 shares ($1.3M) on or after .
Shares originally obtained via Stock Plan Activity.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Published results
Quarterly report for Q2 FY2026
Revenue +296.1% · Operating margin +290.9 pts · Gross profit +351.6% — against Q2 FY2025
Read the filingMade a Regulation FD disclosure
Read the filingHeld a shareholder vote
Read the filingPublished results
Read the filingQuarterly report for Q1 FY2026
Revenue +229.6% · Operating margin +217.2 pts · Gross profit +261.4% — against Q1 FY2025
Read the filingMade a Regulation FD disclosure · Reported another event
Read the filingProxy statement for a shareholder meeting
Read the filingMade a Regulation FD disclosure · Reported another event
Read the filingAnnual report for FY2025
Revenue +66.7% · Operating margin +35.9 pts · Gross profit +73.9% — against FY2024
Read the filingHad a director or senior officer leave or join · Published results
Read the filingMade a Regulation FD disclosure
Read the filingMade a Regulation FD disclosure · Reported another event
Read the filingMade a Regulation FD disclosure · Reported another event
Read the filingQuarterly report for Q3 FY2025
Revenue +52.4% · Operating margin −28.7 pts · Gross profit +56.4% — against Q3 FY2024
Read the filingPublished results
Read the filingMade a Regulation FD disclosure · Reported another event
Read the filingPublished results
Read the filingSource: Exhibit 21 of the 10-K filed 2026-02-19. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Yahoo Finance ·
Insmed Appoints Two New Directors to Its Board
Yahoo Finance ·
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan
Yahoo Finance ·
Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
Yahoo Finance ·
Does Insmed (INSM) CFO Exit With Reaffirmed Guidance Clarify Or Complicate Its Growth Narrative?
Yahoo Finance ·
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
Yahoo Finance ·
Insmed stock falls as CFO Sara Bonstein to step down
Yahoo Finance ·
Insmed Announces CFO Transition
Yahoo Finance ·
Did FDA Priority Review of ARIKAYCE ENCORE Data Just Shift Insmed's (INSM) Investment Narrative?
Yahoo Finance ·
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
Yahoo Finance ·
The Fund Exited Insmed (INSM) After the Investment Thesis Played Out
Yahoo Finance ·
Insmed Expands Community Impact During Fifth Annual Global Day of Good
Yahoo Finance ·
Primary sources and further research